Abstract:
BENZOYLGUANIDINES OF THE FORMULA I IN WHICH: R(1) TO R(4) HAVE THE MEANINGS GIVEN IN THE CLAIMS, ARE ANTIARRHYTHMIC PHARMACEUTICALS, HAVING A CARDIOPROTECTIVE COMPONENT, WHICH ARE ALSO VALUABLE FOR THE PREVENTION OF ISCHEMICALLY INDUCED DAMAGE, IN PARTICULAR IN ASSOCIATION WITH THE TRIGGERING OF ISCHEMICALLY INDUCED CARDIAC ARRHYTHMIAS. AS A CONSEQUENCE OF INHIBITING THE CELLULAR NA+/H+ EXCHANGE MECHANISM, THEY ARE USED FOR TREATING ACUTE OR CHRONICDAMAGE TRIGGERED BY ISCHEMIA. IN ADDITION TO THIS, THEY ARE NOTABLE FOR THEIR STRONG INHIBITORY EFFECT ON THE PROLIFERATION OF CELLS. THEY ARE SUITABLE FOR PREVENTING THE GENESIS OF HIGH BLOOD PRESSURE.
Abstract:
Compounds of the formula (I) in which the symbols have the following meaning: X represents a monocyclic radical having 3, 4 or 5 ring atoms, R , R , R , R , R , R and R is, for example, an alkyl radical q is zero or 1 L is, for example, the methylene group A is the radical, for example, of a heterocycle are highly effective as antagonists of angiotensin II receptors. They can be used as pharmaceuticals or diagnostics.
Abstract:
In the present invention there are described novel compounds of the general formula I, in which Re1, Re2, Re3, Re4 and Re5 represents independently on each other a hydrogen or fluorine atom, whereby at least one from the Re1 to Re5 radicals must be fluorine, Re6 represents hydrogen, alkyl containing 1 to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms or optionally substituted phenyl and Re7 is independently the same as Re6, as well as their pharmaceutically acceptable salts. The indicated compounds are affective inhibitors of cellular exchange of Nae+/He+ ions and they are therefore suitable for treating all diseases caused by increased exchange of Nae+/He ions. There is further described a process for preparing the above specified compounds and their use as medicaments or diagnostic agents. Described are also medicaments in which the indicated compounds are comprised.
Abstract:
Disclosed is benzoylguanidine being represented by 4-(2'-fluoro-2'-propyl)benzoylguanidine-hydrochloride, 4-(2'-trifluormethylethyl)benzoylguanidine-hydrochloride or 3-methylsulfonyl-4-(2'-trifluormethylethyl)benzoylguanidine-hydrochloride, its use as a medicament and a medicament in which the benzoylguanidine is comprised as an active substance.
Abstract:
Benzoyl guanidine derivs. of formula (I) and their salts are new: one of R1-R3 = Het (linked by C or N), SR10, OR10, NR10R11 or CR10R11R12; and the other two of R1-R3 = H, halo, CN, X(CH2)p(CqF2q+1), SOuR22, CONR23R24, COR25, SO2NR26R27, 1-8C alkyl, 2-8C alkenyl, CmH2mR14, OR35 or NR35R36; R4, R5 = H, 1-4C alkyl, Fl, Cl, OR32, NR33R34 or CrF2r+1; R10 = CnH2n-Het; Het = 1-9C heteroaryl-N-oxide (opt. substd. by 1-3 F, Cl, CF3, OMe, OH, NH2, NHMe or NMe2); R11, R12 = as R10, H or 1-4C alkyl; R14 = 3-9C cycloalkyl or phenyl (opt. by 1-3 F, Cl, CF3, Me, OMe, NH2, NHMe or NMe2); R11, R12 = as R10, H or 1-4C alkyl; R14 = 3-8C cycloalkyl or phenyl (opt. substd. by 1-3 F, Cl, CF3, Me, OMe, NH2, NHMe or NMe2); X = a bond, O, S or NR28; R22 = 1-8C alkyl, 2-6C alkenyl, CmH2mR29 or CF3; R23, R25, R26 = H or as R22; R24, R27 = H or 1-4C alkyl; or R23 + R24, R26 + R27 = (CH2)4 or (CH2)5 (both opt. with a CH2 replaced by O, S, NH, NMe or N-benzyl); R28 = H or 1-3C alkyl; R29 = 3-7C cycloalkyl or phenyl (opt. mono- or tri-substd. by F, Cl, CF3, Me, OMe or NR30R31; R30, R31 = H or 1-4C alkyl; R35, R36 = H or 1-6C alkyl; or R35 + R36 = (CH2)y (opt with a CH2 replaced by O, S, NH, NMe or N-benzyl); R32-R34 = H or 1-3C alkyl; n, p, u = 0-2; m = 0-4; r = 1-4; q = 0-6; y = 4-7. Also claimed are cpds. of formula (IIIA); A = Cl, OR45, OH, OM or imidazol-1-yl; M = alkali or alkaline earth metal ion; and R45 = 1-8C alkyl or 1-4C alkylphenyl.
Abstract:
Thiophenylalkenylcarboxylic acid guanidide derivatives of formula (I) and their salts are new. at least one of R1-R3 = Op(CH2)sCqF2q+1, R40CO or R31SOk; and the others = H, F, Cl, Br, I, CN, OnaCmaH2ma+1 or OgaCraH2raR10; p = 0 or 1; s = 0-4; q = 1-8; k = 0-2; R40, R31 = 1-8C alkyl, 1-8C perfluoroalkyl, 3-8C cycloalkyl or Ph (optionally substituted by 1-3 F, Cl, CF3, Me or OMe) or NR41R42; R41,R42 = H, 1-4C alkyl or 1-4C perfluoroalkyl; or R41+R42 = (CH2)x in which a CH2 group may be replaced by O, S, NH, NMe or N-benzyl; x = 4 or 5; na = 0 or 1; ma = 0-8; ga = 0 or 1; ra = 0-4; R10 = 3-8C cycloalkyl or Ph (optionally substituted by 1-3 F, Cl, CF3, Me or OMe); R4, R5 = H, F, Cl, Br, I, CN, 1-8C alkyl, 1-8C perfluoroalkyl, 3-8C cycloalkyl or Ph (optionally substituted by 1-3 F, Cl, CF3, Me, OMe or NR14R15); R14, R15 = H, 1-4C alkyl or 1-4C perfluoroalkyl.
Abstract:
Phenylalkyl (oxy or amino) carbonylguanidine cpds. of formula (I) are new. R1-R3 = Y-Phe, Py, Q-Phe', Het, SR25, OR25, NR25R26, CR25R26R27, En-CvH2v-G-A-R51, H, F, Cl, Br, I, CN, T(CH2)h(ClF2l+1), SOlR31, CONR32R33, COR34, SO2NR45R46, CF2R64, CFR65R66, CFÄ(CF2)qCF3ÜR65, CÄ(CF2)pCF3Ü=CR65R66, OR67, NR67R68, 1-8C alkyl, 2-8C alkenyl or (CH2)mR14; Phe = phenyl, (substd. by one R8 gp. and opt. substd. by 1 or 2 of R'); R' = F, Cl, CF3, Me, OH, OMe or NR15R16; Het = 1-9 heteroaryl, bonded by C or N (opt. substd. by 1-3 or R'); R15, R16, R56 = H or Me; Y = bond, CH2, O, S or NR9; R8 = SOa(NR98)bNR99R10 or SOa(NR98)bNR95-C(=NR94)NR92R93; a = 1 or 2; b = 0 or 1; a+b = 2; R10, R98, R99 = H, Me, benzyl, 2-8C alkyl (opt. substd. by NR11R12 or NR13-A'-NR37R38) or 0-8 alkyl (substd. by CR39R40-CR41R42A"NR43R44); or R99+R10 = 4-6C n-alkylene (opt. with one CH2 replace by O, S, NH, NMe or N-benzyl); A' = 2-8C alkylene; A" = 0-8C alkylene; R11-R13, R23, R24 R37, R38, R43, R44 = H, 1-8C alkyl or benzyl; R39-R42 = H, 4-8C alkyl, phenyl, 1-3C alkyl (opt. substd. by phenyl) (where the phenyl gps. are opt. substd. by F, Cl, CF3, Me or OMe); Py = pyrrol-(1,2 or 3)-yl (opt. substd. by 1-4 of F, Cl, Br, I, CN, 2-8C alkanoyl, 2-8C alkoxycarbonyl, CHO, COOH, CF3, Me or OMe); m, h, l, d, r, p, q = 0-2; s is not defined; R14 = 3-8C cycloalkyl or phenyl(opt. substd. by 1-3 of F, Cl, CF3, Me, OMe and NR15R16); Q = bond, O, S or NR18; Phe' = phenyl (substd. by (CH2)kCHR17COR20 and opt. substd. by one or 2 R'); R17 = OR21 or NR21R22; R20 = OR23 or NR23R24; R22 = H, 1-8C alkyl, 1-8C alkanoyl, 1-8C alkoxycarbonyl, benzyl or benzoyloxycarbonyl; R21 = as R22 or trityl; k, z = 1-4; R25 = 0-2C alkyl substd. by Het or its N-oxide; R26, R27 = H as for R25, H or 1-4C alkyl; T = as Q but not butylimino; i = 2-6; R31 = 1-8C alkyl, 3-6C alkenyl, (CH2)nR48 or CF3; R32,R34,R45 = H or as for R31; n, v = 0-4; R47 R69-R71 = H or 1-3C alkyl; R48 = 3-7C cycloalkyl or phenyl (opt. substd. by 1-3 or F, Cl, CF3, Me, OMe and NR49R50); R33, R46 = H or 1-4C alkyl; or R32+R33, R45+R46 = (CH2)5 or (CH2)6 (both opt. with one CH2 replaced by O, S, NH, NMe or N-benzyl); R51 = basic, protonisable residue ( i.e. NR52R53, C(=NR54)NR52R51 or NR55-C(=NR54)NR52R53) or a basic 1-9C heteroaryl ring; R52-R55 = H or 1-4C alkyl or R52+R53 = C4H8 or A1; or R53+R54, R54+R55 or R52+R55 = C2H4 or A2; A1 =C5H10, C6H12 or C7H14 (all with one C atom opt. replaced by O, SOd or NR56); A2 = C3H6, C4H8 or C5H10 (all with one C opt. replaced by O, SOd or NR56); A = CeH2e (opt. with one C replaced by O, CO, CH(OR57), SOr, NR57,CON(R57), SO2N(R57), NH-CO-NR57 or SO2NHCONR57); e = 0-10; G = phenylene (opt. substd. by one or two of Me, OMe, F, Cl, Br, I, CF3, SOsMe or SOsNR61R62; w = 0 or 1; E = O, CO, CH(OR63), S, SO, SO2, NH, or NMe; R64 = 1-4C alkyl or 3-7C cycloalkyl; R67, R68 = H or 1-6C alkyl; or R67+R68 = (CH2)4-7, opt. with one CH2 replaced by O, S, SO2, NH, NMe or N-benzyl; R4, R5 = H, 1-4C alkyl, F, Cl, OR69, NR70R71 or CzF2z+1; X = O or NR72; R6, R7, R9, R18, R49, R50, R61, R62, R65, R66, R72, R92-R95 = H or 1-4C alkyl; provided that R1-R7 and R72 are not all H.
Abstract:
Benzoylguanidines of formula (I) and their salts are new. R1 and R3 = H, halogen, CN, NO2, 1-8C alkyl, 3-8C cycloalkyl, Oa(CH2)b(CF2)cCF3, S(O)mR5, SO2NR6R7, SR11, OR11, CR11R12R13 or phenyl, naphthyl, biphenylyl or C- or N-bonded 1-9C heteroaryl gps. opt. substd. by 1-3 of F, Cl, CF3, Me, OMe, OH, NH2, NHMe and NMe2; a = 0 or 1; b = 0-2; c = 0-3; m = 0-2; R5 = 1-8C alkyl, 3-6C alkenyl, CF3 or CnH2n-R8; R6 = H, or as for R5; R7 = H or 1-4C alkyl; or R6+R7 = tetra- or pentamethylene, opt. with a CH2 gp. replaced by O, S, NH, NMe or NCH2Ph; n = 0-4; R8 = 3-7C cycloalkyl, or phenyl opt. substd. by 1-3 of F, Cl, CF3, Me, OMe and NR9R10; R9 and R10 = H or 1-4C alkyl; R11 = 3-8C cycloalkyl; (3-8C)cycloalkyl(1-2C)alkyl; or 1-9C heteroaryl or phenyl opt. substd. by 1-3 of F, Cl, CF3, OMe, OH, NH2, NHMe and NMe2; R12 and R13 = H, 1-4C alkyl or gps. as defined for R11; R2 = CF2R14, CF(R15)(R16), CF(Rf)-R15 or CRf=C(R15)(R16); R14 = 1-4C alkyl or 3-6C cycloalkyl; R15 and R16 = H or 1-4C alkyl; Rf = 1-3C perfluoro-n-alkyl; R4 = H, 1-3C alkyl, F, Cl, Br, I, CN or (CH2)s(CF2)tCF3; s = 0 or 1; t = 0-2.
Abstract:
Fluorocinnamoyl guanidine cpds. of formula (I) and their salts are new. R1-R5 = H or F, provided at least one is F; R6, R7 = H, 1-8C alkyl, 3-8C cycloalkyl, or phenyl (opt. substd. by 1-3 of F, Cl, CF3, Me, OMe and NR9R10; R9, R10 = H, 1-4C alkyl or 1-4C perfluoroalkyl.